The use of iron to increase red cell mass

Canadian Journal of Anesthesia

Volumn 50, Issue 6 SUPPL., 2003, Pages

  Beris, Photis ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS ION; HEMOGLOBIN; IRON; IRON DEXTRAN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SUCCINIC ACID;

ANAPHYLAXIS; ANEMIA; ARTHRALGIA; BLOOD TRANSFUSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG COATING; DRUG EFFECT; DRUG INDICATION; DRUG POTENTIATION; ELECTIVE SURGERY; ERYTHROCYTE COUNT; ERYTHROCYTE LIFESPAN; ERYTHROCYTE VOLUME; ERYTHROPOIESIS; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOTENSION; INJECTION PAIN; IRON DEFICIENCY; IRON OVERLOAD; MALAISE; MYALGIA; NAUSEA; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SKIN DISCOLORATION; URTICARIA;

ERYTHROCYTE VOLUME; ERYTHROPOIESIS; HUMANS; IRON;

EID: 0041534384     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Williamson L. Homologous blood transfusion: the risks and alternatives. Br J Haematol 1994; 88: 451-8.
2. Goodnough LT, Skikne B, Grugnara C. Erythropoietin, iron and erythropoiesis. Blood 2000; 96: 823-33.
3. Kasper SM, Lazansky H, Stark C, Klimek M, Laubinger R, Börner U. Efficacy of oral iron supplementation is not enhanced by additional intravenous iron during autologous blood donation. Transfusion 1998; 38: 764-70.
4. Weisbach V, Skoda P, Rippel R, et al. Oral or intravenous iron as an adjuvant to autologous blood donation in elective surgery: a randomized, controlled study. Transfusion 1999; 39: 465-72.
5. Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJM, van de Wiel A. The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion 1992; 32: 162-5.
6. Beris P, Mermillod B, Levy G, et al. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation. A prospective study. Vox Sang 1993; 65: 212-8.
7. Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of regeneration after blood loss. Arch Int Med 1953; 92: 341-8.
8. Olijhoek G, Megens JGN, Musto P, et al. Role of oral versus i.v. iron supplementation in the erythropoietic response to rHuEPO: A randomized, placebo-controlled trial. Transfusion 2001; 41: 957-63.
9. Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in non-anemic orthopedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, efficacy. Transfusion 1994; 34: 66-71.
10. Brugnara C, Chambers LA, Malynne E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993; 81: 956-64.
11. Rohling RG, Zimmermann AP, Breymann C. Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. J Hemother Stem Cell Res 2000; 9: 497-500.
12. De Gobbi M, Pasquero P, Brunello F, et al. Juvenile hemochromatosis associated with β-thalassemia treated by phlebotomy and recombinant human erythropoietin. Haematologica 2000; 85: 865-7.
13. MacDougall IC. How to get the best out of r-HuEpo. Nephrol Dial Transplant 1995; 10(suppl. 12): 85-91.
14. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57: 136-41.
15. MacDougall IC. Optimizing erythropoietin therapy. Curr Opin in Hematol 1999; 6: 121-6.
16. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997-4; 89: 4248-67.
17. Means RT. Progress in understanding the pathogenesis of anemia of chronic disease. Blood 1992; 80: 1639-47.
18. Mittermaier C, Kurz M, Rosskopf K, et al. Autologous blood donation for surgery in inflammatory bowel disease - a report of six cases. J Gastroenterol 1999; 37: 1169-73.
19. Gasche C, Dejaco C, Reinisch W, Tillinger W, Waldhoer T, Fueger GF. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60: 262-7.
20. Tanaka N, Ito K, Ishii S, Yamazaki I. Autologous blood transfusion with recombinant erythropoietin treatment in anaemic patients with rheumatoid arthritis. Clin Rheumatol 1999; 18: 293-8.
21. Biesma DH, van de Wiel A, Beguin Y, Kraaijenhagen RJ, Marx JIM. Post-operative erythropoiesis is limited by the inflammatory effect of surgery on iron metabolism. Eur J Clin Invest 1995; 25: 383-9.
22. Breymann C, Richter C, Hüttner C, Huch R, Huch A. Effectiveness of recombinant erythropoietin and iron sucrose vs iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis. Eur J Clin Invest 2000; 30: 154-61.
23. Mercuriali F, Zanella A, Barosi G, et al. Use of erythropoietin to increase the volume of autologous blood donated by orthopedic patients. Transfusion 1993; 33: 55-60.
24. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn's disease. Ann Intern Med 1997; 126: 782-7.
25. Lee GR. Iron deficiency and iron-deficiency anemia. In: Lee GR, Foerster J, Lukens J, Paraskeva F, Greer JP. Rodgers GM (Eds.). Wintrobe's Clinical Hematology, 10th ed. Williams & Wilkins; 1999: 999-1010.
26. Tarng DC, Huang TP, Wei YH. Erythropoietin and iron: the role of ascorbic acid. Nephrol Dial Transplant 2001; 16(suppl. 1S): 35-9.
27. Brise H, Hallberg L. Iron absorption studies. Acta Med Scand 1962; 171(suppl. 376): 1-8.
28. Hallberg L, Norrby A, Solvell L. Oral iron with succinic acid in the treatment of iron-deficiency anemia. An evaluation based on measurements of iron absorption using a whole body counter and a double radio iron technique. Scand J Haematol 1971; 8: 104-11.
29. Hallberg L, Ryttinger L, Solvell L. Side effects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand 1966; 459(Suppl): 3-10.
30. Kerr DNS, Davidson S. Gastrointestinal intolerance to oral iron preparations. Lancet 1958; 2: 489.
31. Baird IM, Wlaters RL, Sutton DR. Absorption of slow-release iron and effects of ascorbic acid in normal subjects and after partial gastrectomy. Br J Med 1974; 4: 505-8.
32. Greenberg G. Sarcoma after intramuscular iron injection. Br Med J 1976; 1: 1508-9.
33. Van Wyck DB, Cavallo G, Spinowiitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36: 88-97.
34. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13: 381-4.
35. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients in dialysis. Am J Kidney Dis 2001; 37: 879-83.
36. Bolanos L, Castro P, Falcon TG, Mouzo R, Varela JM. Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of Epo rHu administration in hemodialysis patients. Am J Nephrol 2002; 22: 67-72.
37. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186: 518-22.
38. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-31.
39. Swain RA, Kaplan B, Montgomery E. Iron deficiency anemia. When is parenteral therapy warranted? Postgrad Med 1996; 100: 181-93.
40. Becker CE, MacGregor RR, Walker KS, Jandl JH. Fatal anaphylaxis after intramuscular iron-dextran. Ann Intern Med 1966; 65: 745-8.
41. Geisser P, Baer M, Schaub E. Structure/histotoxicity, relationship of parenteral iron preparations. Drug Res 1992; 42: 1439-52.
42. Chandler G, Harchowal J, MacDougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidn Dis 2001; 38: 988-91.
43. Anatkov A, Gekova K. The use of large intravenous doses of iron in the treatment of iron-deficiency anemia. Probl Hematol Blood Transf Med Physiocult 1979; 13: 295-8.
44. Danielson BG, Salmonson T, Derendorf H, Geissetr P. Pharmacokinetics of iron (III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittel-Forschung/Drug Research 1996; 461: 615-21.
45. De Pree C, Mermillod B, Hoffmeyer P, Beris P. Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (≥ 5 units): a randomized study. Transfusion 1997; 37: 708-14.
46. Kooistra MP, Kersting S, Gosriwatana I, et al. Nontransferrin-bound iron in the plasma of hemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32: 36-41.
47. Cighetti G, Duca L, Bortone L, Sala S, et al. Oxidative status and malondialdehyde in β-thalassemia patients. Eur J Clin Invest 2002; 32(suppl 1): 55-60.
48. Rooyakkers TM, Stroes ESG, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32(suppl 1): 9-16.
49. Marx JJM, van Asbeck BS. Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen radical-mediated tissue damage. Acta Haematol 1996; 95: 49-62.
50. Witzum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
51. Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002; 32(suppl 1): 50-4.